Apollomics, Inc. announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer, effective immediately. Dr. Plunkett brings to the company over 25 years of diverse strategic and financial experience within the biopharmaceutical sector, most recently as Chief Financial Officer at Aeovian Pharmaceuticals. Prior to Aeovian, he was Chief Financial Officer at Imago Biosciences (acquired by Merck), where he led the efforts for the company?s $155 million Nasdaq initial public offering (IPO).

He was previously Chief Financial Officer at Nkarta Therapeutics, where he led the efforts for its $290 million Nasdaq IPO. He has held positions including Chief Business Officer at CTI BioPharma (acquired by SOBI), where he led a variety of financing and corporate development transactions. Earlier in his career, Dr. Plunkett held a variety of positions at CIBC World Markets and its U.S. successor Oppenheimer & Co., including Managing Director, Head of West Coast Biotechnology.

Dr. Plunkett received his B.S. in chemistry from Harvey Mudd College and a Ph.D. in organic chemistry from the University of California, Berkeley.